Data from Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry

作者：Arianna Marinello, Julia Rotow, Meghanne Lomibao, Daniela Miliziano, Rita Leporati, Jamie Feng, Giulio Metro, Mariana Brandão, Teresa Gorria, Amin H. Nassar, Fabrizio Citarella, Matteo Fila, Vincent Fallet, Biagio Ricciuti, Skyler Taylor, Jordi Remón, David Planchard, Narjust Florez, Benjamin Besse, Alexander Drilon, Mihaela Aldea · 年份：2026 · DOI：10.1158/1078-0432.c.8568795 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment、Lung Cancer Research Studies

<div>AbstractPurpose:In RET-rearranged non–small cell lung cancer (NSCLC), treatment options after first-generation selective RET inhibitors (SRI) are limited, and the value of SRI retreatment remains unclear. This study evaluates outcomes of SRI retreatment.Experimental Design:This multicenter retrospective study included patients with advanced RET-rearranged NSCLC who received ≥2 SRI-based therapy lines. Of 411 SRI-treated patients, 41 (10%) underwent SRI retreatment. Outcomes included objective response rate (ORR), progression-free survival (PFS), 6-month PFS, time to treatment failure, adverse events (AE).Results:Among 41 patients, 14 (34%) discontinued the initial SRI because of toxicity and 27 (66%) because of progression. After discontinuation for toxicity, all switched to an alternate SRI, achieving an ORR of 67%, median PFS of 9.9 months, and 6-month PFS of 80.3%. AEs reoccurred in nine patients (64%), with grade ≥3 AEs in 3 (21%) who switched at full dose. Among patients who discontinued because of progression, SRI monotherapy (n = 13) achieved an ORR of 23%, median PFS of 7 months, and 6-month PFS of 61.5%. Benefit was observed in patients with brain-only or oligoprogressive disease or dose reduction on first SRI. Combination therapy (n = 14; targeted agents, n = 11; chemotherapy, n = 3) achieved an O...

Data from Retreatment with First-Generation Selective RET Inhibitors in &lt;i&gt;RET&lt;/i&gt;-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry

Data from Retreatment with First-Generation Selective RET Inhibitors in <i>RET</i>-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry